Trump-Era Pharmaceutical Tariff Exemptions for EU, Japan Recalled

During his presidency, Donald Trump’s administration established new tariffs on pharmaceutical imports, though these duties were not uniformly applied across all nations. Countries with pre-existing trade agreements with the United States that included specific drug provisions, such as the European Union and Japan, were granted exemptions or reduced rates. White House officials at the time confirmed that duties on pharmaceuticals from the EU would be capped at 15% under their framework deal, with similar arrangements for Japanese drugs reflecting their respective pacts. This policy aimed to provide relief to key economic partners, ensuring tariff rates on Japanese pharmaceuticals and semiconductors did not exceed those applied to other allies like the EU.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.